Chiara Riganti

• 2002-2006: research fellow at the Department of Genetics, Biology and Biochemistry, laboratory of  Biochemistry, and at Center for Experimental Research and Medical Studies, Onco-hematology  Subalpine Centre, University of Torino  
• 2006-2009: tenure-track assistant professor of Biochemistry, Dept. of Genetics, Biology and  Biochemistry, University of Torino 
• 2009-2016: tenured assistant professor of Biochemistry, Dept. of Genetics, Biology and  Biochemistry, and Dept. of Oncology, University of Torino 
• 2010: visiting scientist at Institut Cochin (Laboratoire de Biologie de l’endothelium cerebrale, prof.  Pierre-Olivier Couraud), Universitè Renè Descartes, Paris 
• 2011 and 2013: visiting professor at Weizmann Institute of Science (Dept. of Molecular Genetics;  prof. Menachem Rubinstein), Rehovot, Israel 
• 2016-2021: associate professor of Biochemistry, Dept. of Oncology, University of Torino 2021-present: full professor of Biochemistry, Dept. of Oncology, University of Torino 

• Molecular and metabolic bases of multidrug resistance (MDR) in cancer cells
• Molecular and metabolic bases of immune-resistance/immune-evasion in cancer cells
• Metabolic dysfunctions of mitochondria and endoplasmic reticulum linking chemoresistance and  immune-resistance/immune-escape in cancer cells 
• Targeting cholesterol metabolism as a new chemo-immune-sensitizing approach 5) Nanomedicine-based approach to reverse chemoresistance and immune-resistance/immune evasion 

International grants as PI:  

• 2022-2023: H2020-IG17104; PANDORA-A Pan-European Educational Platform on Multidrug  Resistant Tumours and Personalised Cancer Treatment 
• 2018-2021: H2020-CA17104; STRATAGEM-New diagnostic and therapeutic tools against  multidrug resistant tumours 

National Grants as PI: 

• 2023-2025: PRIN 2022; Inducing BRCAness in pancreatic cancer by modulating a glycolytic  branch 
• 2022-2023: Compagnia di San Paolo; Real-time monitoring of drug response in non-small cell  lung cancer patient avatars 
• 2021-2023: CRT; A biological passport to rationalize the use of the immunotherapy in oncological  patients in Piemonte 
• 2019-2023: AIRC IG21408; Tipping the balance between ABCB1/ABCC1 and ABCA1: a new  approach to reverse chemo-immuno-resistance in solid tumors 
• 2018-2020: CRT; A preclinical platform to optimize the efficacy of immuno-therapy in women  with non-small cell lung cancer
• 2015-2018: AIRC IG15232; Dissecting the endoplasmic reticulum-mitochondria network to  reverse chemo-immunoresistance of cancer cells 
• 2017-2019: CRT; Building a pre-clinical platform for the diagnosis and treatment of pleural malignant  mesothelioma in Piemonte 
• 2013-2016: FIRB 2012; Optimization of the oncological therapy: new drugs against Multidrug  Resistance 
• 2011-2014: AIRC MFAG11475; A new pharmacological strategy to contemporarily reverse  chemo- and immuno-resistance in human tumors 
• 2009-2011: Compagnia di San Paolo; A novel “Trojan horse” approach to increase chemotherapy  efficacy in brain tumors

• Anobile DP, Salaroglio IC, Tabbò F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E,  Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, Riganti C. Autocrine 17-β estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell  lung cancer. Clin Cancer Res. 2023, doi: 10.1158/1078-0432.CCR-22-3949 
• Polónia B, Xavier CPR, Kopecka J, Riganti C, Vasconcelos MH. The role of Extracellular Vesicles in  glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance. Cytokine  Growth Factor Rev. 2023, doi: 10.1016/j.cytogfr.2023.05.001. 
• Salaroglio IC, Belisario DC, Akman M, La Vecchia S, Godel M, Anobile DP, Ortone G, Digiovanni S,  Fontana S, Costamagna C, Rubinstein M, Kopecka J, Riganti C. Mitochondrial ROS drive resistance to  chemotherapy and immune-killing in hypoxic non-small cell lung cancer. J Exp Clin Cancer Res 2022, 41:243  4) Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat 2021, 18: 100787 
• Villa C, Umbach A, Legato M, Riganti C, Jones R, Martini B, Boido M, Medana C, Facchinetti I, Barni D,  Pinto M, Arguello T, Belicchi M, Fagiolari G, Liaci C, Moggio M, Ruffo R, Moraes CT, Monguzzi A, Merlo  GR, Torrente T. Treatment with ROS detoxifying gold clusters alleviates the progressive functional decline in  a mouse model of Friedreich’s Ataxia. Sci Transl Med 2021, 13(607):eabe1633 
• Xu X, Tassone B, Ostano P, Katarkar A, Proust T, Joseph J-M, Riganti C, Chiorino G, Kutalik Z, Lefort K,  Dotto GP. Different self-renewal and oncogenic potential of keratinocytes from Black versus White populations  linked to OXPHOS and hydroxysteroid dehydrogenase HSD17B7 gene activity. EMBO Mol Med 2021,  13(7):e14133 
• Fiorito V, Allocco A, Petrillo S, Gazzano E, Torretta S, Marchi S, Destefanis F, Pacelli C, Audrito V, Provero  P, Medico E, Chiabrando D, Porporato PE, Cancelliere C, Bardelli A, Trusolino L, Capitanio N, Deaglio S,  Altruda F, Pinton P, Cardaci S, Riganti C, Tolosano E. The heme synthesis-export system: a regulator of the  tricarboxylic acid cycle flux and oxidative phosphorylation. Cell Rep 2021, 35(11):109252 
• Kopecka J, Trouillas P, Čipak Gašparović A, Gazzano E, Assaraf YG, Riganti C. Phospholipids and  cholesterol: inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat 2020,  49:100670 
• Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V,  Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C. Potential diagnostic and  prognostic role of micro-environment in malignant pleural mesothelioma. J Thor Oncol 2019, 14(8):1458-1471  10) Alexa-Stratulat T, Pešić M, Čipak Gašparović A, Trougakos IP, Riganti C. What sustains the multidrug  resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resist  Updat 2019, 46:100643  
• Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-ellatef Abd-elrahman GEF, Massaia  M, Donadelli M, Rubinstein M, Riganti C*, Kopecka J*. Increasing intratumor C/EBP-β LIP and nitric oxide  levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res 2018; 37:286  *co-last authors 
• Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno  I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C. Folate-targeted  liposomal nitrooxy-doxorubicin: an effective tool against P-glycoprotein-positive and folate receptor-positive  tumors. J Control Release 2018; 270:37-52 
• Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, Riganti  C*, Massaia M*. Mechanisms of phosphoantigen release and Vγ9Vδ2 T-cell activation by dendritic cells. Nat  Commun 2017, 8:15663 * co-last author 
• Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, Riganti C. PERK  induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer 2017, 16:e91 
• Riganti C, Kopecka J, Panada E, Barak S, Rubinstein M. The Role of C/EBP-β LIP in Multidrug Resistance.  J Natl Cancer Inst 2015, 107(5):djv046 
• Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo  AM, Riganti C. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating  cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 2013, 12(1):e137 17) Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D,  Schiffer D. Temozolomide down-regulates P-glycoprotein expression in glioblastoma stem cells by interfering  with the Wnt3a/GSK3/β-catenin pathway. Neuro-Oncol 2013, 15(11):1502-17 
• De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. iNOS activity is  necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer 2009, 8:108 
• Campia I, Gazzano E, Pescarmona G, Ghigo D, Bosia A, Riganti C. Digoxin and ouabain increase the  synthesis of cholesterol in human liver cells. Cell Mol Life Sci. 2009, 66:1580-94 
• Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A. Nitric oxide reverts  the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005,  65(2):516-25

Check the full list on Pubmed